A Safety and Efficacy Study of BCD-080 Compared to Clexan for Deep Vein Thrombosis Prophylaxis at Orthopedic Surgeries
- First Posted Date
- 2015-02-23
- Last Posted Date
- 2016-10-24
- Lead Sponsor
- Biocad
- Target Recruit Count
- 124
- Registration Number
- NCT02368314
- Locations
- 🇷🇺
Railroad Clinical Hospital at the station Chelyabinsk, Chelyabinsk, Russian Federation
Open Label Study of Tolerability, Pharmacokinetics and Pharmacodynamics of BCD-054 (Pegylated Interferon Beta-1a), IM and SC, Compared to Rebif® and Avonex® in Healthy Volunteers
- First Posted Date
- 2015-02-10
- Last Posted Date
- 2017-04-10
- Lead Sponsor
- Biocad
- Target Recruit Count
- 60
- Registration Number
- NCT02359877
- Locations
- 🇷🇺
OOO "BioEk", Saint-Petersburg, Russian Federation
Comparative Evaluation of Pharmacokinetics and Safety of BCD-055 and Remicade in Patients With Ankylosing Spondylitis
- Conditions
- Interventions
- First Posted Date
- 2015-02-10
- Last Posted Date
- 2016-06-08
- Lead Sponsor
- Biocad
- Target Recruit Count
- 90
- Registration Number
- NCT02359903
- Locations
- 🇧🇾
Vitebsk Regional Clinical Hospital, Vitebsk, Belarus
🇷🇺Chelyabinsk Regional Clinical hospital, Chelyabinsk, Russian Federation
🇷🇺Nizhegorodskaya Regional Clinical Hospital named after N.A. Semashko, N.Novgorod, Russian Federation
Study of the Efficacy and Safety of Empegfilgrastim for Neutropenia Prophylaxis in Breast Cancer Patients
- First Posted Date
- 2014-04-04
- Last Posted Date
- 2016-10-24
- Lead Sponsor
- Biocad
- Target Recruit Count
- 135
- Registration Number
- NCT02104830
- Locations
- 🇷🇺
Pyatigorsk Oncology Center, Pyatigorsk, Russian Federation
🇷🇺Perm Region Oncology Dispensary, Perm, Russian Federation
🇷🇺Clinical Hospital at Chelyabinsk Railway Station, Chelyabinsk, Russian Federation
An Open-label Randomized Multicenter Phase III Clinical Study Comparing Safety and Efficacy of Algeron (Cepeginterferon Alfa-2b) and and PegIntron (Peginterferon Alfa-2b) in Combination With Ribavirin as Combined Treatment of Chronic Hepatitis C in Human Immunodeficiency Virus-1 Infected Patients
- Conditions
- Interventions
- First Posted Date
- 2014-04-03
- Last Posted Date
- 2018-08-09
- Lead Sponsor
- Biocad
- Target Recruit Count
- 140
- Registration Number
- NCT02103439
- Locations
- 🇷🇺
State Institution of Nizhny Novgorod region "Regional Center for Prevention and Control of AIDS and other infectious diseases", Nizhny Novgorod, Russian Federation
🇷🇺State Budgetary Higher Vocational Education Institution Pacific State Medical University, Ministry of Health of the Russian Federation, Vladivostok, Russian Federation
🇷🇺State Public Healthcare Institution National Center for the Prevention and Control of AIDS and other infectious diseases of the Ministry of Health of the Republic of Tatarstan, Kazan, Republic Of Tatarstan, Russian Federation
Safety and Efficacy Study of BCD-021 Compared to Lucentis® in Patients With Neovascular Wet Age-related Macular Degeneration
- Conditions
- Interventions
- First Posted Date
- 2014-01-15
- Last Posted Date
- 2016-03-31
- Lead Sponsor
- Biocad
- Registration Number
- NCT02036723
- Locations
- 🇷🇺
Scientific and Research Institute named after Helmholtz, Moscow, Russian Federation
🇷🇺Regional Clinical Ophthalmic Hospital named TI Yeroshevsky, Samara, Russian Federation
🇧🇷Hospital dos Olhos do Paraná, Curitiba, Paraná, Brazil
An Open-label Comparative Efficacy and Safety Study of Algeron (Cepeginterferon Alfa-2b) in Treatment-naive Patients With Chronic Hepatitis C
- First Posted Date
- 2013-06-28
- Last Posted Date
- 2018-07-16
- Lead Sponsor
- Biocad
- Target Recruit Count
- 170
- Registration Number
- NCT01889433
- Locations
- 🇮🇳
M V Hospital & Research Center, Lucknow, India
🇮🇳Medipoint Hospitals Pvt. Ltd., Pune, India
🇷🇺State Budgetary Higher Vocational Education Institution I.M. Sechenov First Moscow State Medical University, Moscow, Russian Federation
Pharmacokinetics and Pharmacodynamics Study of BCD-033 Compared to Rebif® in Healthy Volunteers
- First Posted Date
- 2013-01-11
- Last Posted Date
- 2016-05-04
- Lead Sponsor
- Biocad
- Target Recruit Count
- 32
- Registration Number
- NCT01766024
- Locations
- 🇷🇺
City Mariin Hospital, St. Petersburg, Russian Federation
A Safety and Efficacy Study of BCD-022 With Paclitaxel Compared to Herceptin With Paclitaxel in HER2+ Metastatic Breast Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2013-01-09
- Last Posted Date
- 2018-11-29
- Lead Sponsor
- Biocad
- Target Recruit Count
- 225
- Registration Number
- NCT01764022
- Locations
- 🇧🇾
Gomel Region Clinical Oncology Dispensary, Gomel, Belarus
🇧🇾Grodno Regional Hospital, Grodno, Belarus
🇮🇳HCG Bangalore Institute of Oncology, Bangalore, India
A Safety and Efficacy Study of BCD-021 With Paclitaxel and Carboplatin Compared to Avastin With Paclitaxel and Carboplatin in Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-01-09
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- Biocad
- Target Recruit Count
- 353
- Registration Number
- NCT01763645
- Locations
- 🇷🇺
Murmansk Regional Oncology Dispensary, Murmansk, Russian Federation
🇧🇾Gomel Regional Clinical Oncology Dispensary, Gomel, Belarus
🇮🇳HCG Bangalore Institute of Oncology, Bangalore, India